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OBJECTIVES This study was designed to establish a patient-controlled, ambulatory norepinephrine
treatment of refractory orthostatic hypotension due to primary autonomic failure.
BACKGROUND Autonomic dysfunction leads to disabling postural hypotension. Particularly in primary
autonomic dysfunction, repeated syncope and immobilization can be the result. Medical
treatment of orthostatic hypotension often fails in advanced cases.
METHODS Ambulatory, patient-controlled norepinephrine therapy was initiated in six patients with
orthostatic hypotension due to primary autonomic failure that had been refractory to
conventional treatment. Before this therapy, three patients were bedridden; one was
immobilized in a wheelchair. All had recurrent syncope and tolerated upright tilt-table testing
for less than 15 min despite extensive medical treatment. For ambulatory treatment, a
port-a-cath system was implanted and, using a CADD ambulatory infusion pump, norepi-
nephrine was infused in individually adjusted dosages.
RESULTS Norepinephrine infusion therapy enabled all patients to sit, stay and walk around for more
than 45 min. One patient died after a five-year treatment period, another after nine months
because of nonhemorrhagic brain stem infarctions, both in the absence of norepinephrine
treatment. The remaining four patients are still mobile after a period of 19, 10, 9 and 7
months, respectively. None of them has suffered complications due to arterial hypo- or
hypertension, and there has been no infection of the infusion system.
CONCLUSIONS In these selected patients with refractory orthostatic hypotension due to primary autonomic
dysfunction, ambulatory norepinephrine infusion therapy has proved to be a promising new
therapeutic option. Further long-term studies including more patients are necessary to assess
additional indications, reliability and safety of this new method. (J Am Coll Cardiol 2001;37:
219–23) © 2001 by the American College of Cardiology
Patients with severe orthostatic hypotension due to auto-
nomic dysfunction have a severely impaired quality of life.
Besides other neurological problems, orthostatic hypoten-
sion is one of the leading symptoms and, if advanced, is
often refractory to conventional medical treatment. Because
of the postural hypotension, recurrent presyncope or syn-
cope, patients are often immobilized. Most adolescent
patients with primary autonomic orthostatic hypotension
have either Shy-Drager syndrome (multiple system atrophy)
or Bradbury-Eggleston syndrome (idiopathic orthostatic
hypotension, pure autonomic failure) (1).
Despite the limited reliability of plasma catecholamine
measurements in the supine and upright positions to estab-
lish the autonomic origin of orthostatic hypotension (2),
administration of exogenous norepinephrine can maintain
an adequate blood pressure (BP) level and can help to avoid
orthostatic hypotension (3). Thus, the aim of this study was
to establish a new long-term and ambulatory treatment of
otherwise refractory cases of orthostatic hypotension. An
ambulatory norepinephrine-infusion system was used to
treat orthostatic hypotension in selected patients with Shy-
Drager or Bradbury-Eggleston syndrome.
METHODS
Patients and conventional medical treatment. In six pa-
tients with autonomic failure and orthostatic hypotension
refractory to conventional therapy, ambulatory patient-
controlled norepinephrine-infusion therapy was studied
(Table 1). The diagnoses of autonomic failure and ortho-
static hypotension were based on the characteristic medical
history, physical and extensive neurological examination,
autonomic testing and repeated upright tilt-table tests
(4–8). Over a period of at least three months, all patients
received nonpharmacological and pharmacological therapy
of increasing intensity. Basic therapy consisted of increased
fluid and salt intake, elastic stockings, balneotherapy and
professional tilt training (5,9,10). Pharmacological treat-
ment started with augmenting dosages of fludrocortisone,
directly and indirectly acting sympathomimetics (mido-
drine, norfenefrine, yohimbine, amezinium) and erythro-
poietin (11–15).
Norepinephrine treatment. The intensive nonpharmaco-
logical and pharmacological therapy did not improve ortho-
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static hypotension and the associated symptoms in these
patients (Table 1); three of them were still bedridden, and
one patient with Shy-Drager syndrome was still confined to
his wheelchair. Therefore, we tested the effects of intrave-
nous infusion of norepinephrine. We administered norepi-
nephrine in increasing individual dosages (5 to 20 ng/kg
body weight/min) using a temporary intravenous indwelling
catheter and an infusion pump (Original Perfusor Braun, B.
Braun Melsungen, Melsungen, Germany). Blood pressure
was continuously monitored (Dinamap). The administra-
tion of norepinephrine was started in the supine position.
After systolic BP had risen about 20 to 30 mm Hg, the
patients were allowed to sit up. Then the patients were
mobilized, and norepinephrine dosages were adjusted sev-
eral times during standing and stopped before sitting or
lying down. A bolus application on demand was necessary to
maintain adequate BP while changing from supine to sitting
or from sitting to an upright position. Additionally, it was
necessary to work out two different dosages, one for sitting
and a higher one for standing position in some patients.
Success of the temporary norepinephrine infusion was the
requirement for the implantation of a permanent
intravenous-infusion system.
Permanent norepinephrine infusion. After elucidation
about potential hazards of a continuous and self-controlled
norepinephrine therapy (e.g., infections, embolization, hy-
pertension and stroke), written informed consent was ob-
tained. A port-a-cath (SIMS Deltec Inc., St. Paul, Minne-
sota) system was implanted, and every patient was taught to
handle an ambulatory infusion pump (CADD, SIMS
Deltec Inc., St. Paul, Minnesota). In cooperation with the
patients and their relatives and during continuous noninva-
sive BP monitoring, individual dosages for sitting, standing
and walking were established. Individual programming of
the infusion pump was necessary to find an optimal treat-
ment regimen. In general, mobilization and ambulation of
the patients with Bradbury-Eggleston syndrome was much
easier than it was for the patients with accompanying
Parkinson symptoms (Shy-Drager syndrome).
Before entering an upright or sitting position, the patient
had to switch on the system to start the continuous
administration of norepinephrine. Additional bolus on de-
mand were given to fill the port-a-cath system and to
change from a supine to a sitting or upright position. The
pump was switched off or adjusted to a lower infusion rate
immediately before sitting or lying down to avoid episodes
of severe hypertension in supine or sitting positions.
Follow-up. After discharge from the hospital, follow-up
visits at least every three months were arranged in our
Abbreviations and Acronyms
BP 5 blood pressure
HUT5 hea-up tilt table test
MAP5 mean arterial blood pressure
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outpatient clinic. During these visits, the history and a full
physical examination were obtained, and repeated BP mea-
surements, including 24-h ambulatory measurements, were
taken to determine whether the infusion dosage was still
optimally adjusted. Special attention was taken to maintain
the integrity of the infusion system and to watch for signs of
infection. The family physician, a surgeon or an anesthesi-
ologist in cooperation with a local pharmacy replaced drug
cassettes, port-needles and infusion systems.
Parameters of successful treatment. Success of the ther-
apy was assessed as degree of mobilization, including deter-
mination of unimpaired walking distance, 60° upright tilt-
table tests and 24-h ambulatory BP monitoring.
Ethics. Written informed consent was obtained. The local
ethics committee approved the study protocol, and all
investigations were conducted according to Good Clinical
Practice guidelines.
RESULTS
Symptoms and syncope. Symptoms of orthostatic hypo-
tension, like dizziness, blurred vision, dyspnea and nausea,
were noticeably improved in all patients and limited to
errors in operating the infusion pump. These consisted of
starting the infusion late on the one hand or unnecessary
bolus applications with consecutive short hypertensive epi-
sodes on the other hand. No syncope occurred during
appropriate norepinephrine infusion.
Walking distance. During continuous norepinephrine in-
fusion, all patients were mobilized and enabled to walk
around unaided. None of the patients was bedridden or
confined to a wheelchair anymore. The walking distance in
patients with Bradbury-Eggleston syndrome was unlimited,
whereas it was finite in patients with Shy-Drager syndrome.
Nevertheless, the latter increased their distance about 4 to
25-fold compared with conventional medical treatment.
Tilt-table testing. Tilt-table results during patient-
controlled norepinephrine infusion improved markedly
compared with the initial testing or combined nonpharma-
cological and pharmacological (conventional) treatment
(Table 1). As an example of successful norepinephrine
therapy, Figure 1 shows the tilt-table results of a patient
with Shy-Drager syndrome (Patient 4). During conven-
tional treatment, orthostatic hypotension with syncope oc-
curred after 10 min at a mean arterial BP of 50 mm Hg,
whereas norepinephrine infusion enabled the patient to
tolerate 45 min of tilt-table testing without symptoms. In
both cases, heart rate did not change notably.
Ambulatory BP measurements. Intermittent and contin-
uous 24-h BP measurements showed markedly reduced
episodes of orthostatic hypotension during norepinephrine
infusion therapy. Figure 2 shows the example of a patient
with Shy-Drager syndrome (Patient 4) in whom recurrent
episodes of orthostatic hypotension were successfully
treated with the new therapy. In general, supine hyper-
tensive episodes were markedly decreased compared with
conventional treatment, whereas short episodes of hyper-
tension occurred during a delayed turn off while sitting or
lying down or if inappropriate bolus applications were given.
Long-term follow-up. Ambulatory norepinephrine ther-
apy was successful initially in all six patients in the program.
The longest therapy period was five years in a female patient
with Shy-Drager syndrome (Patient 6). This patient died at
age 75 years because of a nonhemorrhagic brain stem
infarction that occurred one morning while she tried to get
up without starting the infusion pump.
A second non-hemorrhagic stroke was responsible for the
death of a 72-year-old patient with Shy-Drager syndrome
(Patient 5). In this case, ambulatory infusion therapy was
stopped six months earlier. Increasing compliance and
coordination problems had led the family physician to stop
the norepinephrine treatment. Although conventional ther-
apy had been reintroduced, the patient was confined to his
wheelchair again.
The other four patients are still being treated successfully
and have been mobile for a period of 19, 10, 9 and 7
months, respectively. Infections or embolization have not
occurred in any case; hospitalization has been necessary in
only one patient (Patient 1) at one-year follow-up.
DISCUSSION
Autonomic orthostatic hypotension is a rare but severely
disabling condition. Impaired autonomic reflexes with in-
adequate rise of plasma catecholamine levels and an almost
fixed heart rate lead to a decrease in BP because of the
deficient vasoconstrictor tone and the lack of increase in
heart rate (16,17). The upright position is associated with
symptoms like blurred vision, light-headedness, dizziness,
head and neck discomfort, presyncope or even syncope.
Conventional treatment. The conventional approach in
treating patients with autonomic orthostatic hypotension
consists of a combination of nonpharmacological and phar-
macological regimens of increasing intensity (5,9 –
12,14,15,18,19). Regardless of optimal nonpharmacological
or pharmacological treatment, the autonomic insufficiency
Figure 1. Changes of MAP during a 60° head-up tilt-table test (HUT) in
a patient with Shy-Drager syndrome (Patient 4). Syncope occurred after
10 min during conventional nonpharmacological and pharmacological
treatment (lower line), whereas a symptom-free 45 min test was possible
with the patient-controlled, ambulatory norepinephrine treatment (upper
line). Heart rate remained stationary in both cases. MAP 5 mean arterial
blood pressure.
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can lead to immobilization and confinement to bed in
advanced cases. Another disadvantage of the conventional
medical treatment is the development or the worsening of
hypertension in patients who remain in the supine position
(20).
Norepinephrine infusion. Polinsky et al. (3) first used a
temporary norepinephrine infusion to overcome orthostatic
hypotension during tilt-table testing in two patients with
Shy-Drager syndrome. The aim of the current study was to
establish an ambulatory and long-term treatment of ortho-
static hypotension in cases of severe autonomic failure. We
tested the effects of a patient-controlled, ambulatory nor-
epinephrine infusion therapy on BP in supine, sitting and
upright positions. In all patients, norepinephrine infusion
prevented symptomatic orthostatic hypotension; mobiliza-
tion was possible in all cases, and some patients were able to
walk for the first time in months.
Infusion system. The port-a-cath system is a widely used
system for intermittent application of different chemother-
apeutic agents, mostly in patients with cancer or AIDS. In
patients with an impaired immune system, the overall
complication rate is 13% to 19%; infections occur in 2% to
5% and occlusions in 3% to 6.5% of all cases (21,22). We
have not observed complications related to the implantable
venous catheter system.
Advantages and limitations. The major advantages of the
new therapeutic tool were the ability to mobilize patients
previously confined to bed and to avoid syncope. The
efficacy has been well-documented in symptom-free
head-up tilt-table tests and in increased walking distance.
Treatment on demand meant that pre-existing hypertension
present in the supine position was not aggravated. The
requirement of compliant patients, who can handle the
system, is a possible limitation of this new therapeutic
approach. Mobilization proved to be much easier in patients
without accompanying Parkinson-like neurological symp-
toms (Bradbury-Eggleston syndrome) than it was for pa-
tients with Shy-Drager syndrome. Even this therapeutic
approach will not prevent serious complications of the
underlying disease in all instances. But although difficulties
arose in some cases, an improved quality of life was
conveyed to patients with both syndromes.
Conclusions. In selected patients with severe and refrac-
tory orthostatic hypotension due to autonomic failure,
ambulatory and patient-controlled norepinephrine treat-
ment seems to be a promising long-term therapy in com-
pliant patients. However, further studies enrolling larger
patient numbers are necessary to establish the role of
ambulatory norepinephrine infusion in the treatment of
autonomic orthostatic hypotension and to assess additional
indications, reliability and safety of this new method.
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